Stay tuned and follow the latest developments and news in Molecular Oncology.
Genekor Medical is pleased to announce its participation in the ASCO Annual Meeting 2026, taking place on May 29 – June 2, 2026, in Chicago, Illinois, with four scientific online publications.
Genekor’s Online Publications at ASCO 2026
Comparative evaluation of targeted RNA sequencing and RNA-exome sequencing for fusion detection in soft tissue sarcomas
This study evaluates the diagnostic utility of RNA-exome sequencing compared with targeted RNA NGS for the detection of sarcoma-associated gene fusions.
https://www.asco.org/abstracts-presentations/259500
Clinical utility of comprehensive molecular profiling in Cholangiocarcinoma
This publication highlights the clinical value of comprehensive genomic profiling in cholangiocarcinoma, aiming to identify clinically significant and actionable molecular alterations.
https://www.asco.org/abstracts-presentations/264971
Real-world data on CLDN18.2 expression in gastric and gastroesophageal cancer patients
This study presents real-world data on CLDN18.2 expression in patients with gastric and gastroesophageal junction cancer.
https://www.asco.org/abstracts-presentations/264958
Comprehensive genomic profiling of patients with Cancer of Unknown Primary (CUP)
This publication assesses the clinical utility of comprehensive genomic profiling in patients with Cancer of Unknown Primary.
https://www.asco.org/abstracts-presentations/264634
Genekor’s scientific team remains committed to generating and sharing meaningful scientific insights with the medical community, highlighting the value of molecular diagnostics, comprehensive genomic profiling, and precision medicine in oncology.